171 related articles for article (PubMed ID: 22167413)
1. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Perl AE; Kasner MT; Shank D; Luger SM; Carroll M
Clin Cancer Res; 2012 Mar; 18(6):1716-25. PubMed ID: 22167413
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Kasner MT; Mick R; Jeschke GR; Carabasi M; Filicko-O'Hara J; Flomenberg N; Frey NV; Hexner EO; Luger SM; Loren AW; Mangan JK; Wagner JL; Weiss M; Carroll M; Perl AE
Invest New Drugs; 2018 Aug; 36(4):657-666. PubMed ID: 29607465
[TBL] [Abstract][Full Text] [Related]
3. Phospho-specific flow: fixating on the target.
Levis M
Clin Cancer Res; 2012 Mar; 18(6):1493-5. PubMed ID: 22302900
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
[TBL] [Abstract][Full Text] [Related]
5. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients.
Chow S; Minden MD; Hedley DW
Exp Hematol; 2006 Sep; 34(9):1183-91. PubMed ID: 16939811
[TBL] [Abstract][Full Text] [Related]
6. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
7. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.
Iwenofu OH; Lackman RD; Staddon AP; Goodwin DG; Haupt HM; Brooks JS
Mod Pathol; 2008 Mar; 21(3):231-7. PubMed ID: 18157089
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
9. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.
Zeng Z; Shi YX; Tsao T; Qiu Y; Kornblau SM; Baggerly KA; Liu W; Jessen K; Liu Y; Kantarjian H; Rommel C; Fruman DA; Andreeff M; Konopleva M
Blood; 2012 Sep; 120(13):2679-89. PubMed ID: 22826565
[TBL] [Abstract][Full Text] [Related]
10. Phenotypically Dormant and Immature Leukaemia Cells Display Increased Ribosomal Protein S6 Phosphorylation.
Pallis M; Harvey T; Russell N
PLoS One; 2016; 11(3):e0151480. PubMed ID: 26985829
[TBL] [Abstract][Full Text] [Related]
11. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
12. Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.
Grundy M; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(5):e0196805. PubMed ID: 29723246
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Boehrer S; Galluzzi L; Lainey E; Bouteloup C; Tailler M; Harper F; Pierron G; Adès L; Thépot S; Sébert M; Gardin C; de Botton S; Fenaux P; Kroemer G
Cell Cycle; 2011 Sep; 10(18):3168-75. PubMed ID: 21897118
[TBL] [Abstract][Full Text] [Related]
14. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
15. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
16. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
[TBL] [Abstract][Full Text] [Related]
17. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
19. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M
Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
